A year after FDA approval in heart failure (HF) with LVEF of 40% or higher, new ACC guidance and trial subanalyses are shaping how pharmacists use finerenone.
Commentary|Podcasts|August 26, 2025
From Guidelines to Action: Pharmacy’s Role in Hypertension Management
Advertisement
In this episode, host Craig Beavers sits down with Gary Owen, clinical pharmacist and manager of Population Health Pharmacy Services at Vanderbilt University Medical Center, to discuss the newly updated ACC/AHA hypertension guidelines and what they mean for pharmacists. Gary shares how his team supports primary care providers across the state through collaborative practice agreements, innovative telephonic care models, and value-based care initiatives. The conversation explores how pharmacists can be pivotal in optimizing medication management, improving patient access, and driving better outcomes in chronic disease care.
Read the
Advertisement
Related to this article
Sea buckthorn is a commonly used herbal for respiratory health—US pharmacists are knowledgeable in educating patients on herbals, especially during the cold season.
Impostor syndrome prevalence in oncology pharmacists is a complex topic that is not well described.
VAX-31 met all primary end points against PCV20 and PCV21 in the pivotal phase 3 OPUS-1 trial.
Neither the lipoprotein(a) [Lp(a)]–lowering antisense oligonucleotide nor the IL-6 inhibitor cut CV events in phase 3, but patients with high Lp(a) may still bring questions to pharmacists.
Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.
Community pharmacies are access points, safe places, and sources of stability when everything else feels uncertain.
In the phase 3 B-Well trials, about 1 in 5 adults reached functional cure after a fixed course, but a boxed warning makes monitoring key for pharmacists.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Operationalizing Therapy and Managing Hypophosphatemia Risk at UPMC
2
Fall 2026 Quiz: Test Your Pharmacy Knowledge!
3
Could Divarasib Challenge Existing KRAS G12C Inhibitors in Lung Cancer?
4
FDA Approves Bepirovirsen, First ASO for Chronic Hepatitis B
5